Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLOG
Read on
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
Redefining CAR-T Speed and Strength with DAR-T™: A Conversation with Nicholas Kirian
In this Q&A, Nicholas Kirian, Senior Manager of MSAT, discusses how DAR-T™, an autologous CAR-T platform, is addressing longstanding challenges in...
Cell Therapy Innovations: Reducing Costs to Improve Patient Access
Cell therapies offer life-changing treatments for patients with limited options, but face commercialization challenges due to high costs, ability to...
Presentation: Rapid Multi-Omics Cell Therapy Characterization and QC
On February 5th at 1:00 pm, join Neeraj Salathia, Director of Advanced Genomics, for a presentation on Rapid Multi-Omics Cell Therapy...
Whitepaper: 3-Day Short Cycle CAR-T Manufacturing Process
The conventional manufacturing process for the generation of activated CAR-T cells can typically take 7 to 9 days or even longer. Resilience has...
Presentation: Expedited Cell Therapy QC: Sample in, to QC Report in 48 Hours
On January 22nd at 4:00 pm, join Mazen Karaman, Director of Platform Management – Cell Therapy, for a presentation on Expedited Cell Therapy QC.
Accelerating Clinical Timelines of Induced Pluripotent Stem Cells (iPSCs) with Pluristyx
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
